Stay updated with breaking news from Nasdaq Thrx. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Denali Advisors LLC boosted its stake in shares of Theseus Pharmaceuticals, Inc. (NASDAQ:THRX – Free Report) by 675.2% during the 3rd quarter, according to its most recent filing with the SEC. The firm owned 127,900 shares of the company’s stock after purchasing an additional 111,400 shares during the period. Denali Advisors LLC owned approximately 0.29% […]
Theseus Pharmaceuticals (NASDAQ:THRX – Get Free Report) and MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Free Report) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, valuation, profitability, analyst recommendations, earnings and dividends. Insider and Institutional Ownership 91.1% of Theseus Pharmaceuticals […]
Theseus Pharmaceuticals, Inc. (NASDAQ:THRX – Get Free Report)’s share price traded down 0.4% during trading on Tuesday . The stock traded as low as $2.27 and last traded at $2.30. 105,762 shares changed hands during trading, a decline of 68% from the average session volume of 335,687 shares. The stock had previously closed at $2.31. […]
Wedbush reiterated their outperform rating on shares of Theseus Pharmaceuticals (NASDAQ:THRX – Free Report) in a research report sent to investors on Thursday, RTT News reports. The brokerage currently has a $7.00 target price on the stock. Wedbush also issued estimates for Theseus Pharmaceuticals’ Q1 2024 earnings at ($0.33) EPS, Q2 2024 earnings at ($0.35) […]
Theseus Pharmaceuticals, Inc. (NASDAQ:THRX – Get Free Report) Director Carl L. Gordon bought 479,932 shares of the company’s stock in a transaction on Monday, July 17th. The shares were bought at an average price of $3.05 per share, for a total transaction of $1,463,792.60. Following the completion of the acquisition, the director now directly owns […]